This is disappointing from the point of view of using pregabalin as an alternative AD therapeutic to target BACE1 elevation and dystrophic axons and suggests further study of the use of pregabalin in AD patients to assess effects on pathology. This evidence concerns the gene BACE1 and Alzheimer disease.